Carlos Caldas

Professor of Cancer Medicine

Research Group Home Page:: Caldas Group

Work address:: Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE

Publications:: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

E-pub date: 31 Jul 2019; BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer.

E-pub date: 31 Jul 2019; POSEIDON phase 1b results: safety, efficacy and ctDNA response of taselisib combined with tamoxifen in hormone receptor positive metastatic breast cancer patients.

E-pub date: 31 Jul 2019; 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

E-pub date: 31 May 2019; Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.

E-pub date: 31 May 2019; EN1 is a transcriptional dependency in triple-negative breast cancer associated with brain metastasis.

E-pub date: 31 May 2019; A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.

E-pub date: 30 Apr 2019; The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.

E-pub date: 30 Apr 2019; Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.

E-pub date: 30 Apr 2019; Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.

E-pub date: 31 Mar 2019; EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy.

E-pub date: 31 Mar 2019; Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

E-pub date: 28 Feb 2019; Cancer Treatment in the Genomic Era.

E-pub date: 28 Feb 2019; PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative breast cancer.

E-pub date: 28 Feb 2019; T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.

E-pub date: 28 Feb 2019; The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

E-pub date: 01 Feb 2019; No Association Between Vitamin D Status and Risk of Barrett’s Esophagus or Esophageal Adenocarcinoma-a Mendelian Randomization Study.

E-pub date: 31 Jan 2019; Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

E-pub date: 31 Jan 2019; Genome-wide association study of germline variants and breast cancer-specific mortality.

E-pub date: 31 Jan 2019; Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA.

E-pub date: 31 Dec 2018; The circular RNome of primary breast cancer.

E-pub date: 31 Dec 2018; Cancer Core Europe: A translational research infrastructure for a European mission on cancer.

E-pub date: 31 Dec 2018; Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis.

E-pub date: 30 Nov 2018; miR-342-5p as a potential regulator of HER2 breast cancer cell growth.

E-pub date: 30 Nov 2018; A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

E-pub date: 30 Sep 2018; Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century.

E-pub date: 31 Aug 2018; Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.

E-pub date: 31 Aug 2018; Effects of collection and processing procedures on plasma circulating cell-free DNA from cancer patients.

E-pub date: 31 Jul 2018; SOX4 can redirect TGF-β-mediated SMAD3-transcriptional output in a context-dependent manner to promote tumorigenesis.

E-pub date: 31 Jul 2018; Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.

E-pub date: 31 Jul 2018; MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

E-pub date: 31 Jul 2018; High USP6NL Levels in Breast Cancer Sustain Chronic AKT Phosphorylation and GLUT1 Stability Fueling Aerobic Glycolysis.

E-pub date: 01 Jul 2018; Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers.

E-pub date: 01 Jun 2018; Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.

E-pub date: 01 Jun 2018; Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.

E-pub date: 31 May 2018; Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.

E-pub date: 31 May 2018; Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element.

E-pub date: 31 May 2018; αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.

E-pub date: 17 May 2018; RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

E-pub date: 01 May 2018; Determining Risk of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants.

E-pub date: 01 Apr 2018; Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus.

E-pub date: 15 Mar 2018; Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.

E-pub date: 07 Mar 2018; Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status.

E-pub date: 01 Feb 2018; SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors.

E-pub date: 30 Jan 2018; Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts.

E-pub date: 05 Jan 2018; Body mass index and breast cancer survival: a Mendelian randomization analysis.

E-pub date: 01 Dec 2017; PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

E-pub date: 01 Nov 2017; Germline variation in inflammation-related pathways and risk of Barrett’s oesophagus and oesophageal adenocarcinoma.

E-pub date: 31 Oct 2017; High-risk individuals’ perceptions of reproductive genetic testing for CDH1 mutations.

E-pub date: 31 Oct 2017; Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters.

E-pub date: 31 Oct 2017; A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.

E-pub date: 31 Oct 2017; Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.

E-pub date: 10 Oct 2017; Of mice and men: patient-derived xenografts in cancer medicine.

E-pub date: 01 Oct 2017; The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC).

E-pub date: 31 Aug 2017; Predicting treatment resistance and relapse through circulating DNA.

E-pub date: 31 Aug 2017; The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

E-pub date: 25 Aug 2017; Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.

E-pub date: 01 Aug 2017; Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.

E-pub date: 01 Aug 2017; Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.

E-pub date: 31 Jul 2017; Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

E-pub date: 15 Jul 2017; Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study.

E-pub date: 11 Jul 2017; Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity.

E-pub date: 07 Jul 2017; Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

E-pub date: 01 Jun 2017; Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers.

E-pub date: 18 Apr 2017; Liquid biopsies come of age: towards implementation of circulating tumour DNA.

E-pub date: 01 Apr 2017; Interrogating open issues in cancer precision medicine with patient-derived xenografts.

E-pub date: 01 Apr 2017; Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.

E-pub date: 30 Mar 2017; Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.

E-pub date: 29 Mar 2017; CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.

E-pub date: 17 Feb 2017; Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival.

E-pub date: 01 Feb 2017; Further evidence to support bimodality of oestrogen receptor expression in breast cancer.

E-pub date: 01 Feb 2017; Patient-derived tumour xenografts for breast cancer drug discovery.

E-pub date: 31 Dec 2016; Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study.

E-pub date: 31 Dec 2016; p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis.

E-pub date: 22 Dec 2016; The C/EBPδ protein is stabilized by estrogen receptor α activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer.

E-pub date: 01 Dec 2016; An investigation of the factors effecting high-risk individuals’ decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC).

E-pub date: 31 Oct 2016; Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis.

E-pub date: 31 Oct 2016; Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.

E-pub date: 01 Oct 2016; Nucleosome mapping in plasma DNA predicts cancer gene expression.

E-pub date: 28 Sep 2016; Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

E-pub date: 26 Sep 2016; A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.

E-pub date: 22 Sep 2016; Subtype-specific micro-RNA expression signatures in breast cancer progression.

E-pub date: 01 Sep 2016; Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.

E-pub date: 01 Sep 2016; It’s PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence.

E-pub date: 01 Sep 2016; Consensus on precision medicine for metastatic cancers: a report from the MAP conference.

E-pub date: 31 Aug 2016; The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study.

E-pub date: 31 Aug 2016; Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.

E-pub date: 31 Aug 2016; Modeling Breast Cancer Intertumor and Intratumor Heterogeneity Using Xenografts.

E-pub date: 31 Aug 2016; Stratification and therapeutic potential of PML in metastatic breast cancer.

E-pub date: 24 Aug 2016; Reliable gene expression profiling of formalin-fixed paraffin-embedded breast cancer tissue (FFPE) using cDNA-mediated annealing, extension, selection, and ligation whole-genome (DASL WG) assay.

E-pub date: 20 Aug 2016; SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.

E-pub date: 31 Jul 2016; Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

E-pub date: 01 Jul 2016; Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

E-pub date: 02 Jun 2016; A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.

E-pub date: 01 Jun 2016; Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.

E-pub date: 31 May 2016; The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

E-pub date: 10 May 2016; Facilitating a culture of responsible and effective sharing of cancer genome data.

E-pub date: 05 May 2016; MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

E-pub date: 12 Apr 2016; Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays.

E-pub date: 31 Mar 2016; Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.

E-pub date: 31 Mar 2016; Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.

E-pub date: 16 Feb 2016; Double-stranded microRNA mimics can induce length- and passenger strand-dependent effects in a cell type-specific manner.

E-pub date: 01 Feb 2016; Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

E-pub date: 05 Jan 2016; Expression of androgen receptor splice variants in clinical breast cancers.

E-pub date: 29 Dec 2015; A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.

E-pub date: 29 Dec 2015; Context-Specific Effects of TGF-β/SMAD3 in Cancer Are Modulated by the Epigenome.

E-pub date: 22 Dec 2015; Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

E-pub date: 04 Nov 2015; BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

E-pub date: 31 Oct 2015; APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer.

E-pub date: 06 Oct 2015; Pathway-based personalized analysis of breast cancer expression data.

E-pub date: 31 Aug 2015; Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

E-pub date: 31 Aug 2015; Toward understanding and exploiting tumor heterogeneity.

E-pub date: 31 Aug 2015; Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett’s Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium.

E-pub date: 31 Aug 2015; Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer.

E-pub date: 28 Aug 2015; Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts.

E-pub date: 01 Aug 2015; PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.

E-pub date: 31 Jul 2015; Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer.

E-pub date: 31 Jul 2015; Progesterone receptor modulates ERα action in breast cancer.

E-pub date: 16 Jul 2015; Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel–response.

E-pub date: 01 Jul 2015; Combined Single-Cell Functional and Gene Expression Analysis Resolves Heterogeneity within Stem Cell Populations.

E-pub date: 04 Jun 2015; Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

E-pub date: 01 Jun 2015; Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.

E-pub date: 01 Jun 2015; Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.

E-pub date: 01 Jun 2015; MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene.

E-pub date: 31 May 2015; Identification of novel genetic markers of breast cancer survival.

E-pub date: 31 May 2015; Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

E-pub date: 20 May 2015; Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.

E-pub date: 23 Apr 2015; Common germline polymorphisms associated with breast cancer-specific survival.

E-pub date: 22 Apr 2015; Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.

E-pub date: 01 Apr 2015; Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.

E-pub date: 31 Mar 2015; Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression.

E-pub date: 31 Mar 2015; Intra-tumour signalling entropy determines clinical outcome in breast and lung cancer.

E-pub date: 31 Mar 2015; Prognostic and predictive value of PDL1 expression in breast cancer.

E-pub date: 10 Mar 2015; Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.

E-pub date: 19 Feb 2015; A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

E-pub date: 31 Jan 2015; Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.

E-pub date: 31 Jan 2015; Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.

E-pub date: 31 Jan 2015; The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape.

E-pub date: 22 Jan 2015; Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer.

E-pub date: 20 Jan 2015; A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation.

E-pub date: 09 Jan 2015; BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells.

E-pub date: 09 Jan 2015; eEF2K–a new target in breast cancers with combined inactivation of p53 and PTEN.

E-pub date: 31 Dec 2014; Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer.

E-pub date: 03 Dec 2014; Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells.

E-pub date: 01 Nov 2014; Cancer Core Europe: a consortium to address the cancer care-cancer research continuum challenge.

E-pub date: 01 Nov 2014; Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.

E-pub date: 31 Oct 2014; Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

E-pub date: 23 Sep 2014; Patient-derived xenograft models: an emerging platform for translational cancer research.

E-pub date: 01 Sep 2014; Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis.

E-pub date: 31 Aug 2014; Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

E-pub date: 31 Aug 2014; Genome-driven integrated classification of breast cancer validated in over 7,500 samples.

E-pub date: 28 Aug 2014; Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

E-pub date: 01 Aug 2014; The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study.

E-pub date: 31 Jul 2014; Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance.

E-pub date: 31 Jul 2014; Nuclear CSPP1 expression defined subtypes of basal-like breast cancer.

E-pub date: 15 Jul 2014; TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.

E-pub date: 01 Jul 2014; JARID1B is a luminal lineage-driving oncogene in breast cancer.

E-pub date: 16 Jun 2014; DNA polymerase β deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts.

E-pub date: 31 May 2014; Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.

E-pub date: 01 May 2014; Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy.

E-pub date: 28 Apr 2014; Processed pseudogenes acquired somatically during cancer development.

E-pub date: 09 Apr 2014; Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

E-pub date: 01 Apr 2014; The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31.

E-pub date: 06 Mar 2014; Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.

E-pub date: 01 Feb 2014; Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression.

E-pub date: 31 Jan 2014; A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus.

E-pub date: 31 Dec 2013; Assessing excellence in translational cancer research: a consensus based framework.

E-pub date: 29 Oct 2013; Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial.

E-pub date: 15 Sep 2013; TOX3 mutations in breast cancer.

E-pub date: 31 Aug 2013; Master regulators of FGFR2 signalling and breast cancer risk.

E-pub date: 31 Aug 2013; Finding common regions of alteration in copy number data.

E-pub date: 31 Aug 2013; Improving breast cancer survival analysis through competition-based multidimensional modeling.

E-pub date: 31 Aug 2013; Basic cancer research is essential for the success of personalised medicine.

E-pub date: 31 Aug 2013; A prognostic gene signature for metastasis-free survival of triple negative breast cancer patients.

E-pub date: 31 Aug 2013; Signatures of mutational processes in human cancer.

E-pub date: 22 Aug 2013; Imprinted chromatin around DIRAS3 regulates alternative splicing of GNG12-AS1, a long noncoding RNA.

E-pub date: 08 Aug 2013; Circulating tumor DNA to monitor metastatic breast cancer.

E-pub date: 04 Jul 2013; G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells.

E-pub date: 03 Jul 2013; Multidisciplinary decisions in breast cancer: does the patient receive what the team has recommended?

E-pub date: 25 Jun 2013; Genetic heterogeneity in breast cancer: the road to personalized medicine?

E-pub date: 18 Jun 2013; Video Q&A: molecular profiling of breast cancer.

E-pub date: 18 Jun 2013; The shaping and functional consequences of the microRNA landscape in breast cancer.

E-pub date: 16 May 2013; Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

E-pub date: 02 May 2013; A metadata-aware application for remote scoring and exchange of tissue microarray images.

E-pub date: 01 May 2013; Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer.

E-pub date: 17 Apr 2013; Breast cancer: Tamoxifen–when more might be better.

E-pub date: 31 Mar 2013; Analysis of circulating tumor DNA to monitor metastatic breast cancer.

E-pub date: 28 Mar 2013; A new genome-driven integrated classification of breast cancer and its implications.

E-pub date: 06 Mar 2013; A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial.

E-pub date: 05 Mar 2013; The implications of clonal genome evolution for cancer medicine.

E-pub date: 28 Feb 2013; Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.

E-pub date: 21 Feb 2013; Astronomical algorithms for automated analysis of tissue protein expression in breast cancer.

E-pub date: 19 Feb 2013; Lack of expression of the proteins GMPR2 and PPARα are associated with the basal phenotype and patient outcome in breast cancer.

E-pub date: 31 Jan 2013; Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes.

E-pub date: 22 Dec 2012; DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer.

E-pub date: 22 Dec 2012; Copynumber: Efficient algorithms for single- and multi-track copy number segmentation.

E-pub date: 04 Nov 2012; TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome.

E-pub date: 01 Nov 2012; Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer.

E-pub date: 31 Oct 2012; Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling.

E-pub date: 24 Oct 2012; Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland.

E-pub date: 22 Oct 2012; Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.

E-pub date: 30 Sep 2012; Calling sample mix-ups in cancer population studies.

E-pub date: 31 Aug 2012; TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer.

E-pub date: 31 Aug 2012; Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

E-pub date: 22 Aug 2012; Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue.

E-pub date: 31 Jul 2012; Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

E-pub date: 30 May 2012; Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping.

E-pub date: 30 May 2012; Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.

E-pub date: 22 May 2012; The landscape of cancer genes and mutational processes in breast cancer.

E-pub date: 16 May 2012; Cancer sequencing unravels clonal evolution.

E-pub date: 07 May 2012; The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

E-pub date: 18 Apr 2012; Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers.

E-pub date: 18 Apr 2012; The clonal and mutational evolution spectrum of primary triple-negative breast cancers.

E-pub date: 04 Apr 2012; A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.

E-pub date: 31 Jan 2012; Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.

E-pub date: 04 Jan 2012; The breast cancer genome–a key for better oncology.

E-pub date: 30 Nov 2011; Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma.

E-pub date: 31 Oct 2011; Calpastatin is associated with lymphovascular invasion in breast cancer.

E-pub date: 31 Oct 2011; Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance.

E-pub date: 31 Aug 2011; Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium.

E-pub date: 15 Aug 2011; RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.

E-pub date: 31 Jul 2011; CYP2D6 gene variants and their association with breast cancer susceptibility.

E-pub date: 01 Jun 2011; A population-based validation of the prognostic model PREDICT for early breast cancer.

E-pub date: 31 May 2011; ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.

E-pub date: 31 Mar 2011; Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer.

E-pub date: 15 Feb 2011; A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia.

E-pub date: 31 Dec 2010; Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules.

E-pub date: 04 Nov 2010; Genetics: How to validate a breast cancer prognostic signature.

E-pub date: 01 Nov 2010; From genomic landscapes to personalized cancer management-is there a roadmap?

E-pub date: 31 Oct 2010; The importance of platform annotation in interpreting microarray data.

E-pub date: 31 Aug 2010; PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.

E-pub date: 31 Aug 2010; CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.

E-pub date: 31 Aug 2010; Prognostic gene network modules in breast cancer hold promise.

E-pub date: 31 Aug 2010; PathGrid: a service-orientated architecture for microscopy image analysis.

E-pub date: 28 Aug 2010; Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research.

E-pub date: 31 Jul 2010; Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

E-pub date: 30 Jun 2010; Fine scale mapping of the breast cancer 16q12 locus.

E-pub date: 15 Jun 2010; Genetic predisposition to gastro-oesophageal cancer.

E-pub date: 01 Jun 2010; Micro-RNAs and breast cancer.

E-pub date: 01 Jun 2010; Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.

E-pub date: 31 May 2010; Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression.

E-pub date: 31 May 2010; The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer.

E-pub date: 31 May 2010; Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas.

E-pub date: 31 May 2010; Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.

E-pub date: 25 May 2010; International network of cancer genome projects.

E-pub date: 15 Apr 2010; Common germ-line polymorphism of C1QA and breast cancer survival.

E-pub date: 13 Apr 2010; Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

E-pub date: 31 Mar 2010; Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in breast cancer.

E-pub date: 01 Mar 2010; The pitfalls of platform comparison: DNA copy number array technologies assessed.

E-pub date: 08 Dec 2009; Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer.

E-pub date: 01 Dec 2009; A metadata approach for clinical data management in translational genomics studies in breast cancer.

E-pub date: 30 Nov 2009; Characterisation of microRNA expression in post-natal mouse mammary gland development.

E-pub date: 20 Nov 2009; The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene.

E-pub date: 19 Nov 2009; Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival.

E-pub date: 20 Oct 2009; Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution.

E-pub date: 08 Oct 2009; Tamoxifen: the drug that came in from the cold.

E-pub date: 15 Sep 2009; Triple negative breast cancers: clinical and prognostic implications.

E-pub date: 01 Sep 2009; Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast.

E-pub date: 31 Aug 2009; The breast cancer somatic ‘muta-ome’: tackling the complexity.

E-pub date: 31 Aug 2009; Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer.

E-pub date: 31 Aug 2009; One-stop diagnostic breast clinics: how often are breast cancers missed?

E-pub date: 16 Jun 2009; Molecular classification of solid tumours: towards pathway-driven therapeutics.

E-pub date: 19 May 2009; Germline CDH1 deletions in hereditary diffuse gastric cancer families.

E-pub date: 01 May 2009; Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells.

E-pub date: 01 Feb 2009; DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study.

E-pub date: 31 Dec 2008; Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST).

E-pub date: 01 Nov 2008; Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk.

E-pub date: 01 Nov 2008; Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer.

E-pub date: 01 Nov 2008; High-resolution array CGH clarifies events occurring on 8p in carcinogenesis.

E-pub date: 07 Oct 2008; PMC42, a breast progenitor cancer cell line, has normal-like mRNA and microRNA transcriptomes.

E-pub date: 31 Aug 2008; Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.

E-pub date: 31 Aug 2008; Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients.

E-pub date: 31 Aug 2008; A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer.

E-pub date: 31 Aug 2008; A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer.

E-pub date: 31 Aug 2008; ESR1 gene amplification in breast cancer: a common phenomenon?

E-pub date: 31 Jul 2008; Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.

E-pub date: 29 May 2008; Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.

E-pub date: 06 May 2008; High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.

E-pub date: 01 May 2008; Array comparative genomic hybridization copy number profiling: a new tool for translational research in solid malignancies.

E-pub date: 01 Apr 2008; MicroRNA: implications for cancer.

E-pub date: 31 Jan 2008; Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line.

E-pub date: 15 Jan 2008; The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.

E-pub date: 31 Dec 2007; Regulation of p53 tetramerization and nuclear export by ARC.

E-pub date: 26 Dec 2007; Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis.

E-pub date: 31 Oct 2007; p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing.

E-pub date: 18 Oct 2007; Elucidating the altered transcriptional programs in breast cancer using independent component analysis.

E-pub date: 31 Aug 2007; MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.

E-pub date: 31 Aug 2007; High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.

E-pub date: 31 Aug 2007; An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.

E-pub date: 31 Aug 2007; Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.

E-pub date: 20 Jul 2007; BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines.

E-pub date: 15 Jul 2007; Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event.

E-pub date: 31 May 2007; Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST).

E-pub date: 31 May 2007; Cancer genetics of epigenetic genes.

E-pub date: 15 Apr 2007; Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers.

E-pub date: 22 Mar 2007; Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumors.

E-pub date: 01 Mar 2007; A gene-expression signature to predict survival in breast cancer across independent data sets.

E-pub date: 01 Mar 2007; Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.

E-pub date: 15 Feb 2007; MTAP homozygous deletion: an Achilles heel of human cancers ready for clinical use?

E-pub date: 01 Mar 2005; Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria.

E-pub date: 01 Jul 2004; Clinical implications of E-cadherin associated hereditary diffuse gastric cancer.

E-pub date: 01 Jun 2004; Novel human, mouse and xenopus genes encoding a member of the RAS superfamily of low-molecular-weight GTP-binding proteins and its downregulation in W/WV mouse jejunum.

E-pub date: 01 Feb 2004; EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.

E-pub date: 31 Oct 2003; A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples.

E-pub date: 01 Oct 2003; A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma.

E-pub date: 31 Aug 2003; Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands.

E-pub date: 28 Feb 2003; Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma.

E-pub date: 31 Oct 2002; Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families.

E-pub date: 01 Dec 2001; Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma.

E-pub date: 01 Oct 2001; Report on the first meeting of the International Collaborative Group on Hereditary Gastric Cancer.

E-pub date: 31 Oct 2000; Impact of genomics on drug discovery and clinical medicine.

E-pub date: 01 Jul 2000; Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells.

E-pub date: 30 Sep 1999; Molecular assessment of cancer.

E-pub date: 30 Apr 1998; Exon scrambling of MLL transcripts occur commonly and mimic partial genomic duplication of the gene.

E-pub date: 31 Jan 1998; Cancer genes and molecular oncology in the clinic.

E-pub date: 01 May 1997; EEN encodes for a member of a new family of proteins containing an Src homology 3 domain and is the third gene located on chromosome 19p13 that fuses to MLL in human leukemia.

E-pub date: 28 Feb 1997; Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias.

E-pub date: 01 Feb 1995; Molecular genetic profiles of colitis-associated neoplasms.

E-pub date: 31 Aug 1994; Case report: transverse myelitis associated with Epstein-Barr virus infection.

E-pub date: 01 Jan 1994; Synchronous mature teratomas of the ovary and liver: a case presenting 11 years following chemotherapy for immature teratoma.

E-pub date: 01 Dec 1992; Show all Hide all

Research Integrity Conflict of Interest Disclosure:

Last revised:: 22/10/2018

Company	Active	Research funding	Ownership	Royalty payments	Commitment to carry out work for a fee	Ad hoc reimbursed work	Travel	Gifts/ other
Astra Zeneca	Yes	Yes	No	No	Yes	No	No	No
Roche	No	Yes	No	No	No	No	No	No
Genentech	No	Yes	No	No	No	No	No	No
Servier	Yes	Yes	No	No	No	No	No	No

Disclosure guidelines

Carlos Caldas

Professor of Cancer Medicine

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer.

POSEIDON phase 1b results: safety, efficacy and ctDNA response of taselisib combined with tamoxifen in hormone receptor positive metastatic breast cancer patients.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.

EN1 is a transcriptional dependency in triple-negative breast cancer associated with brain metastasis.

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.

Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.

EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy.

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

Cancer Treatment in the Genomic Era.

PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative breast cancer.

T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

No Association Between Vitamin D Status and Risk of Barrett’s Esophagus or Esophageal Adenocarcinoma-a Mendelian Randomization Study.

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

Genome-wide association study of germline variants and breast cancer-specific mortality.

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA.

The circular RNome of primary breast cancer.

Cancer Core Europe: A translational research infrastructure for a European mission on cancer.

Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis.

miR-342-5p as a potential regulator of HER2 breast cancer cell growth.

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century.

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.

Effects of collection and processing procedures on plasma circulating cell-free DNA from cancer patients.

SOX4 can redirect TGF-β-mediated SMAD3-transcriptional output in a context-dependent manner to promote tumorigenesis.

Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

High USP6NL Levels in Breast Cancer Sustain Chronic AKT Phosphorylation and GLUT1 Stability Fueling Aerobic Glycolysis.

Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers.

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.

Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.

Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.

Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element.

αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

Determining Risk of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants.

Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus.

Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.

Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status.

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors.

Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts.

Body mass index and breast cancer survival: a Mendelian randomization analysis.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Germline variation in inflammation-related pathways and risk of Barrett’s oesophagus and oesophageal adenocarcinoma.

High-risk individuals’ perceptions of reproductive genetic testing for CDH1 mutations.

Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters.

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.

Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.

Of mice and men: patient-derived xenografts in cancer medicine.

The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC).

Predicting treatment resistance and relapse through circulating DNA.

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study.

Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity.

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers.

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.

Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.

Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival.

Further evidence to support bimodality of oestrogen receptor expression in breast cancer.

Patient-derived tumour xenografts for breast cancer drug discovery.

Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study.

p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis.

The C/EBPδ protein is stabilized by estrogen receptor α activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer.

An investigation of the factors effecting high-risk individuals’ decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC).

Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis.

Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.